Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis.

• Tác giả: Filia Apostolakou, Meletios-Athanasios Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Charikleia Gakiopoulou, Maria Gavriatopoulou, Stavroula Giannouli, Nikolaos Kanellias, Efstathios Kastritis, Panagiotis Malandrakis, Smaragdi Marinaki, Magdalini Migkou, Ioannis Ntanasis-Stathopoulos, Asimina Papanikolaou, Ioannis Papassotiriou, Erasmia Psimenou, Vasiliki Spiliopoulou, Evangelos Terpos, Foteini Theodorakakou
• Ngôn ngữ: eng
• Ký hiệu phân loại: 004.2 Systems analysis and design, computer architecture, performance evaluation
• Thông tin xuất bản: United States : American journal of hematology , 2025
• Bộ sưu tập: NCBI
• ID: 749662

Tóm tắt

Cystatin C (CysC) has emerged as a novel and potentially more reliable biomarker for the estimation of glomerular filtration in the general population in patients with various conditions. In AL amyloidosis, the current renal staging system and renal response criteria are based on proteinuria and creatinine-based eGFR. We explored the prognostic role of CysC and of estimation of eGFR based on CysC-based equations in a cohort of 195 patients with newly diagnosed AL amyloidosis with renal involvement. Baseline CysC level was strongly and independently associated with progression to dialysis, and CysC levels ≥ 1.9 mg/L can be used in combination with the current renal staging system to identify patients with different risk of progression to dialysis among renal stages 2 and 3. eGFR based on CysC performed at least similarly to eGFR based on creatinine alone (by CKD-EPI race free formula) and the cutoff of 30 mL/min/1.73 m